ixabepilone

Known as: ixabepilone [Chemical/Ingredient], ixabepilone (oral), Oral Ixabepilone 
An enteric-coated formulation of ixabepilone, a semisynthetic analogue of epothilone B and a non-taxane tubulin inhibitor, with antineoplastic… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
PURPOSE We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
  • Eva S. Thomas
  • Journal of clinical oncology : official journal…
  • 2008
TO THE EDITOR: On behalf of the study investigators, I would like to communicate results of a US Food and Drug Administration… (More)
  • table 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE There is a need for new agents to treat metastatic breast cancer (MBC) in patients for whom anthracycline therapy has… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Ixabepilone is an epothilone B analog that binds to microtubules and results in microtubule stabilization and mitotic… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Ixabepilone (BMS-247550) is an epothilone B analog that stabilizes microtubules and has antitumor activity in taxane… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Tumor necrosis factor (TNF)-alpha, a major proinflammatory cytokine, triggers endothelial cell activation and barrier dysfunction… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Recent preclinical studies have shown that frequent administration in vivo of low doses of chemotherapeutic drugs ("metronomic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations involving tubulin. We report two paclitaxel… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?